Synchrotron Radiation Study of the M2MgSi2O7:Eu2+ Persistent Luminescence Materials
| Autor: | Marco Kirm, Mika Lastusaari, Janne Niittykoski, Jorma Hölsä, Taneli Laamanen, Pavel Novák, Jüri Raud |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Materials science Adolescent rufinamide Band gap Excitation spectra Analytical chemistry Synchrotron radiation therapeutic use [Triazoles] 02 engineering and technology drug therapy [Epilepsy] 010402 general chemistry therapeutic use [Anticonvulsants] 01 natural sciences Ion methods [Drug Therapy Combination] Young Adult Persistent luminescence Double-Blind Method Humans Longitudinal Studies Child Doping DESY Triazoles 021001 nanoscience & nanotechnology 0104 chemical sciences 3. Good health Treatment Outcome Child Preschool ddc:540 Drug Evaluation Female Anticonvulsants 0210 nano-technology Luminescence |
| Zdroj: | ECS transactions 6, 647 (2008). doi:10.1149/1.2938743 |
| ISSN: | 1938-6737 1938-5862 |
| DOI: | 10.1149/1.2938743 |
| Popis: | This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|